News/announcements

 

Bioquell PLC – 2016 Preliminary Results

Bioquell PLC (LSE symbol: BQE), the provider of specialist bio-decontamination systems and services to the international Life Sciences and Healthcare markets, today announces its preliminary results for the year ending 31st December 2016.

 

Read more

Share Buyback Programme

Share Buyback Programme
 
Bioquell announces its intention to reduce its capital by means of purchasing its shares from time to time ("Share Repurchases") using existing cash resources of up to £2.5 million, to make market purchases of up to 1,850,000 shares (the "Maximum Amount").  This amount is within the amount permitted pursuant to the general authority given to it at the Company's General Meeting held on 20 June 2016.  
 
By way of background, at the time of the tender offer which returned £40.8million to shareholders in June 2016 (the “Tender Offer”), the directors stated that should the number of ordinary shares validly tendered under the Tender Offer be less than the maximum permitted under the terms of the Tender Offer, subject to circumstances prevailing following completion of the Tender Offer, the Board intended to return any such balance to Shareholders by means of a market purchase through the London Stock Exchange. 

Read more

Notice of General Meeting

Notice of General Meeting
 
 
The Company is today posting a circular to shareholders to seek shareholder approval for the establishment of a Performance Share Plan.  The meeting is to be held at 10.00am on 24 November 2016 at the offices of Nabarro LLP, 125 London Wall, London, EC2Y 5AL.
 
The circular gives more detail on the proposed Performance Share Plan and is available on the Company’s website.
 
 
For further information contact:
 
Bioquell PLC 01264 835900
Michael Roller Finance Director
Georgina Pope Company Secretary
 

Read more

Circular To Shareholders, Establishment Of Performance Share Plan, Notice Of General Meeting

A notice convening a General Meeting of the Company to be held at 10 a.m. on 24 November 2016 at
the offices of Nabarro LLP at 125 London Wall, London EC2Y 5AL is set out at the end of this
document.
 
A Form of Proxy for use at the General Meeting is enclosed. To be valid, the Form of Proxy should be
completed, signed and returned in accordance with the instructions printed on it to the Company’s
Registrars, Capita Asset Services at PXS 1, 34 Beckenham Road, Beckenham, Kent BR3 4ZF, as
soon as possible but in any event so as to arrive no later than 10 a.m. on 22 November 2016.

Read more

New directorships of directors

In accordance with the Listing Rules of the Financial Conduct Authority, Bioquell PLC (“Bioquell”) discloses that it has been informed that Mr Christopher Mills, a Non-Executive Director of Bioquell, has been appointed as a director of Quantum Pharma Plc and that Mr Ian Johnson, Executive Chairman, has been appointed as non-Executive Chairman of Quantum Pharma Plc.

 

For further information contact:

Bioquell PLC             01264 835900

Ian Johnson             Chairman

Michael Roller           Finance Director

Read more

Board Committee Changes Aug 16

Board Committee Changes Aug 16

Read more

Termination of Strategic Review

Bioquell PLC
 
Termination of Strategic Review
 
 
As a result of the termination of the Strategic Review, announced with the publication of the Company’s interim results earlier today, the Company is no longer in an offer period for the purposes of the Takeover Code and, accordingly, the requirement to make disclosures under Rule 8 of the Code has now ceased.
In accordance with Rule 26.1 of the Code, a copy of this announcement will be published, subject to certain restrictions relating to persons in any restricted jurisdiction, at http://www.bioquell.com
 
 
Ends
 
 
 
For further information contact:
 
Bioquell PLC 01264 835900
Ian Johnson Chairman
Michael Roller Finance Director
 

Read more

Bioquell PLC – 2016 interim results

Bioquell PLC – 2016 interim results
Bioquell PLC (“Bioquell”) (LSE symbol: BQE) - provider of specialist bio-decontamination products and services for the international Life Sciences markets today announces its interim results for the six month period ended 30 June, 2016.
 
Highlights:
Financial
  • Bio-decontamination revenues (excluding defence sales) increased by 8% to £11.1 million (2015: £10.3 million)
  • Overall revenues declined by 3% to £12.1 million (2015: £12.5 million)
  • Non-UK revenues amounted to £9.0 million (2015: £10.0 million) – representing  74% of total revenues
  • Gross margin increased to 46% (2015: 42%)
  • EBITDA increased 14% to £1.6 million (2015: £1.4 million)
  • Earnings per share were 0.8p (2015: 82.5p, 0.2p excluding the profit on disposal of TRaC) 
  • Following the completion of the June tender offer, £40.8 million of cash was returned to shareholders via a share buyback, leaving net cash of £7.3 million at 30 June, 2016 (2015: £47.7 million)
Business activities
  • Strategic review concluded; management restructured and focus on further development and improvement of bio-decontamination business
  • Strong focus on generating recurring revenues from service activities and consumables sales
  • Launch of new fixed (wall-mounted) bio-decontamination system – the Bioquell
  • ‘Flat-screen’
  • US salesforce restructured
Commenting on the 2016 interim results, Ian Johnson, Chairman of Bioquell PLC, said: 
Whilst overall revenues declined slightly as a result of lower defence sales compared with the first half of 2015, I am pleased to report that our bio-decontamination business grew by 8%. Profitability improved as a result of our cost reduction programme – and management continues to seek further improvements in the financial performance of the business through greater focus on the international Life Sciences market and driving up the proportion of recurring revenues.
The Board has now concluded the Strategic Review announced in 2015 and believes that Bioquell shareholders’ interests would best be served by continuing to build a world class bio-decontamination business and focussing on further improving its financial performance.  Accordingly the management of the business will be restructured.   I have become Executive Chairman and the current Chief Executive, Nick Adams, has stepped down.  In addition, Jay LeCoque has joined the board of Bioquell in the new role of Commercial Director.
On behalf of all Bioquell shareholders I would like to thank Nigel Keen for his seven years as Chairman.
I would also like to thank Nick Adams for his substantial contribution as Chief Executive.  Under his leadership Bioquell has changed beyond all recognition from a low technology manufacturer of safety cabinets to a leader in specialist bio-decontamination.  
The Board is confident that the improved financial performance seen in the first half of the year will carry through to the full year.
 
Enquiries:
Ian Johnson Chairman
Michael Roller Finance Director
Bioquell PLC 01264 835900
 

Read more

Result of Tender Offer note 2

Result of Tender Offer

Bioquell PLC announces following the closing of its tender offer, announced earlier today, 20,405,814 ordinary shares of 10p each (the “Shares”) were validly tendered to N+1 Singer for subsequent purchase and cancellation by the Company.

Following the cancellation of the Shares, the Company has 22,938,059 ordinary shares of 10p each in issue.  No ordinary shares are held in treasury.


In accordance with Rule 2.10 of the Code, as at the date of this announcement, the Company confirms that it has 22,938,059 ordinary shares of 10 pence each in issue.”

Ends

Enquiries:

Michael Roller

Bioquell PLC         

01264 835 900

Read more

Result of Tender Offer note 1

The Company today announces the final results of the Tender Offer, details of which were set out in the circular to Shareholders published by the Company on 2 June 2016 (the "Circular").

A total of 20,405,814 Ordinary Shares were validly tendered by Shareholders and accepted for purchase by N+1 Singer at the Tender Price for a total cost of £40.8million. This represents approximately 47 per cent of the Company's current share capital. 

Read more